Market Insights · Mortality Improvement Life settlement mortality improvement trends 2026: SOA MP-2021 status, LE recovery, and buy-side IRR sensitivity. Most mortality articles cover actuarial methodology. This article connects SOA mortality improvement updates, post-pandemic life expectancy recovery, and the troubling age 80+ trend to specific buy-side IRR implications and LE estimate sensitivity for institutional life […]
Market Insights · Carrier Concentration Life settlement carrier concentration 2026: top 5 issuers, AM Best trajectory, and the 3-tier risk framework. Most carrier articles cover product reviews for individual policy buyers. This article analyzes the top 5 carriers in U.S. life settlement secondary market supply from buy-side institutional perspective — Lincoln National, Pacific Life, John […]
Market Insights · Pricing Mechanics Life settlement secondary market pricing 2026: how investors back into the bid. Most life settlement pricing articles explain broker commissions from the seller side. This article walks accredited investors through the NPV math from the buy side — how the institutional bid is built from life expectancy, premium load, and […]
Market Insights · Industry Heritage · 1911–2026 115 years since Grigsby v. Russell: the 1911 Supreme Court ruling that built today’s $4.6B life settlement market. Most Grigsby v. Russell articles retell the basic narrative — Burchard sells his policy to Dr. Grigsby, Supreme Court validates the transaction. This article, published 115 years after Justice Holmes’s […]
Market Insights · Income Strategy Life settlement vs annuity: two alternative income strategies for accredited investors compared. Both bet against life expectancy assumptions — but they work in opposite directions. An honest 8-dimension comparison of life settlement investment vs annuity for accredited investors evaluating income alternatives. By John Sandoval Role Income Strategy Advisor Published May […]
Market Insights · Returns Analysis Life settlement investment returns 8-12%: decomposing the range for accredited investors. An honest decomposition of the 8-12% IRR range — what actually drives it, how longevity variance affects realized outcomes, and how this asset class compares to liquid alternatives in 2026. By John Sandoval Role Investment Returns Specialist Published May […]
Market Insights · Investment Selection Best life settlement investments 2026: a 6-attribute scoring framework for accredited investors. What actually makes a top-tier policy investment in 2026 — the six attributes that separate strong opportunities from weak ones, the macro context shaping pricing, and the diligence checks that matter when you commit capital. By John Sandoval […]
Home Insights Tertiary Life Settlement Market Market Insights · Acquisition Strategy The tertiary life settlement market: where accredited investors actually acquire policies. What the tertiary market actually is, why it matters more than the secondary market for individual accredited investors, the three operational routes to access it, and what changed after the 2022 GWG collapse. […]
Home Insights Are Life Settlements a Good Investment Market Insights · Investment Evaluation Are life settlements a good investment in 2026? An unbiased look at the data. A genuinely balanced assessment of life settlements as an investment — what the industry data actually shows, where the asset class earns its place in institutional portfolios, and […]
Home Insights Tertiary Life Settlement Market Market Insights · Institutional Trading The tertiary life settlement market: what it is and why sophisticated investors are paying attention. Why tertiary market trading volume now exceeds secondary market volume, how the three transaction types work, and what this maturation means for both institutional and individual investors in life […]
